Left Atrial Appendage Occlusion, A Misnomer?: Where Do We Go From Here?

Mayo Clin Proc. 2022 Aug;97(8):1525-1533. doi: 10.1016/j.mayocp.2022.03.026.

Abstract

The importance of the left atrial appendage (LAA) as the source of thromboembolism including stroke in patients with nonvalvular atrial fibrillation is well documented, with more than 90% of ischemic strokes related to a LAA thrombus. Although oral anticoagulation has been the standard of care, approximately 50% to 60% of patients either have contraindications to oral anticoagulation or do not continue the medication beyond the first year. This led to the development of local site-specific therapy to occlude the LAA by either surgical or transcatheter means. Despite marked advancements, incomplete LAA closure with surgical and transcatheter approaches remains frequent. The etiology of incomplete LAA closure and its clinical implications remain unclear. Multiple strategies are in development including changes in deployment techniques, a new device design, and alternative approaches to leak closure.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Appendage* / surgery
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / surgery
  • Humans
  • Stroke* / complications
  • Stroke* / prevention & control
  • Thromboembolism* / drug therapy
  • Thromboembolism* / etiology
  • Thromboembolism* / prevention & control
  • Thrombosis* / complications
  • Thrombosis* / prevention & control
  • Treatment Outcome

Substances

  • Anticoagulants